State of the Art: Concise ReviewBeyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC
Keywords
Cited by (0)
Drs. Nagasaka and Zhu contributed equally to this work.
Disclosure: Dr. Nagasaka has received honorarium from AstraZeneca, Caris Life Sciences, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Blueprint Medicines and Tempus. Dr. Zhu has received honoraria from AstraZeneca, Blueprint, Roche-Foundation Medicine, Roche/Genentech, and Takeda; and had stock ownership of TP Therapuetics until May 2020. Dr. Lim has received honorarium from AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Takeda and research funding from AstraZeneca and Yuhan Corporation. Dr. Greco is an employee of and has stock options in Beta Pharma. Dr. Wu has received honorarium from Roche and AstraZeneca. Dr. Ou has stock ownership and was on the scientific advisory board of Turning Point Therapeutics, Inc. (until February 28, 2019); is a member of the scientific advisory board of Elevation Oncology and has stock ownership in Elevation Oncology, and has received speaker honorarium from Merck, Roche/Genentech, AstraZeneca, Takeda/ARIAD, and Pfizer; and has received advisory fees from Roche/Genentech, AstraZeneca, Takeda/ARIAD, Pfizer, Foundation Medicine Inc., Spectrum, Daiichi Sankyo, and Janssen/Johnson & Johnson.
- 1
The name of ‘Alflutinib’ was changed as per the requirements of the National Pharmacopoeia Committee of China and the “China drug generic naming principle”, and the name of the drug has been changed from ‘Alflutinib’ to ‘Furmonertinib’.